RVPH: Total Utang marang Modal Reviva Pharmaceuticals Holdings, Inc.

Logo perusahaan publik Reviva Pharmaceuticals Holdings, Inc. (RVPH)

The historical price chart for Reviva Pharmaceuticals (RVPH) on GURU.Markets demonstrates a total debt-to-equity ratio of 0.05. Reviva Pharmaceuticals develops medications for bipolar disorder and schizophrenia, aiming to minimize negative therapy side effects for CNS patients. The business's environmental profile is limited to the safe disposal of laboratory waste. Experienced executives are focused on the final testing phases and engagement with regulatory authorities.

RVPH - Total Utang marang Modal Reviva Pharmaceuticals Holdings, Inc. ing rentang 04.07.2022 - 16.05.2026

Rincian metrik lan analitis perusahaan Reviva Pharmaceuticals, Inc. (RVPH)

- rega lan prakiraan konsensus rega:
Bagan rega Reviva Pharmaceuticals Holdings, Inc.|RVPH - Prakiraan gabungan firma investasi
- informasi kapitalisasi pasar:
Kapitalisasi pasar Reviva Pharmaceuticals|RVPH - Total Nilai Perusahaan
- indikator kapitalisasi buku:
Nilai Akuntansi saben Saham Reviva Pharmaceuticals|RVPH - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku revivapharma.com|RVPH - Nilai Agregat Aset
- indikator beban kredit lan likuiditas emiten:
Utang marang Ekuitas Reviva Pharmaceuticals|RVPH - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Reviva Pharmaceuticals|RVPH - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku Reviva Pharmaceuticals|RVPH - Utang jangka dawa|Kewajiban jangka cendhak perusahaan Reviva Pharmaceuticals|Rasio cepet revivapharma.com
- statistik bathi lan rasio pasar:
RVPH - Asil keuangan resik
Pambiji fundamental perusahaan:Reviva Pharmaceuticals Holdings, Inc., RVPH
Barang utama Reviva Pharmaceuticals

The Debt/Equity ratio measures the proportion of borrowed funds relative to equity, determining the company's degree of financial autonomy and level of credit risk. For Reviva Pharmaceuticals (RVPH), which finances the development of neuroleptics through investments, changes in the ratio of total debt to equity reflect balance sheet resilience during periods of zero operating revenue and the quality of asset management.

Pesaing Reviva Pharmaceuticals

Utang marang Ekuitas Biogen|Rasio Utang marang Ekuitas NBIX (Neurocrine)|Total Utang marang Modal RGC|AXSM - Utang marang Modal|ACADIA Pharmaceuticals - Rasio Total Utang marang Ekuitas|Total Utang marang Modal xenon-pharma.com XENE|VKTX - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi SUPN (Supernus Pharmaceuticals, Inc.)|Catalyst Pharmaceuticals Inc (CPRX) - Utang marang Ekuitas|Utang marang Modal Denali Corp (DNLI)|Utang marang Ekuitas Harmony Biosciences|BHVN: Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal AMLX|TRVI - Utang marang Modal|Praxis Medicines - Rasio Total Utang marang Ekuitas|Anavex Life Sciences Corp - Utang marang Ekuitas|CeriBell, Inc. - Total Utang marang Modal|Koefisien Total Utang marang Modal Prothena Corporation PLC PRTA|ALEC (alector.com) - Rasio Total Utang marang Ekuitas|ANNX (Annexon Biosciences) - Utang marang Ekuitas|OMER (Omeros Corp) - Total Utang marang Modal|Total Utang marang Modal Neurogene Therapeutics|Rasio Total Utang marang Ekuitas ACIU (AC Immune)|VYGR (voyagertherapeutics.com) - Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas Neumora Therapeutics, Inc. NMRA|SCLX (Scilex Holding) - Utang Agregat marang Ekuitas|Tevogen Bio Holdings, Inc. - Total Utang marang Modal|Rasio Kabeh Utang marang Dana Pribadi ACOG (Alpha Cognition)|CGTX: Total Utang marang Modal|inhibikase.com (IKT) - Total Utang marang Modal|Utang marang Ekuitas Cassava Sciences|ASRT: Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas Coya Therapeutics, Inc. (COYA)|Rasio Total Utang marang Ekuitas vistagen.com VTGN|Total Utang marang Modal OVID (Ovid Therapeutics)|Total Utang marang Modal acumenpharm.com ABOS|CervoMed - Total Utang marang Modal|Alterity Therapeutics (ATHE) - Rasio Total Utang marang Ekuitas|CLNN: Total Utang marang Modal|Utang marang Modal PepGen (PEPG)|Rasio Total Utang marang Ekuitas JUNS|Total Utang marang Modal relmada.com|Rasio Total Utang marang Ekuitas ANVS (Annovis Bio)|Utang Agregat marang Modal GRCE|Total Utang marang Modal AIFF (Firefly Neuroscience Inc)|Koefisien Total Utang marang Modal ANEW Medical (KLTO)|NeuroSense Therapeutics, Ltd. - Total Utang marang Modal|MetaVia Inc (MTVA) - Rasio Total Utang marang Ekuitas|NRXS: Total Utang marang Modal|Helius Medical Technologies (HSDT) - Total Utang marang Modal|Utang marang Ekuitas Passage Bio Inc.|Utang marang Ekuitas NEUP|Utang marang Ekuitas Minerva Neurosciences (NERV)|Koefisien Total Utang marang Modal athira.com|Utang marang Ekuitas Addex Therapeutics Ltd ADXN|Rasio Kabeh Utang marang Dana Pribadi ALZN|CYCN: Rasio Total Utang marang Ekuitas|PTIX: Utang marang Ekuitas|pasitheaclinics.com (KTTA) - Utang marang Ekuitas|Utang Agregat marang Ekuitas CRGT (Cortigent)|ATXI (Avenue Therapeutics, Inc.) - Total Utang marang Modal|BCLI: Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas Cara Therapeutics, Inc (CARA)|Chromocell - Rasio Utang marang Ekuitas|Total Utang marang Modal ELYM (Eliem Therapeutics Inc.)|Intra-Cellular Therapies Inc. (ITCI) - Utang marang Modal|LBPH: Rasio Total Utang marang Ekuitas|MRNS - Total Utang marang Modal|NKGen (NKGN) - Utang marang Ekuitas|NeuroBo Pharma - Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas Sage Therapeutics, Inc.|Utang marang Modal synaptogen.com SNPX|Utang marang Ekuitas Trevena (TRVN)|VIGL (vigilneuro.com) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal WENA (Anew Medical)|Cerevel Corp (CERE) - Utang marang Modal